Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome

BACKGROUND: Glycemic control and management of dyslipidemia to reduce cardiovascular risk are major therapeutic goals in individuals with type 2 diabetes mellitus (T2DM). This study was performed to evaluate the effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ (...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Barbara C, Tigno, Xenia T, Bénardeau, Agnes, Meyer, Markus, Sebokova, Elena, Mizrahi, Jacques
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037308/
https://www.ncbi.nlm.nih.gov/pubmed/21251281
http://dx.doi.org/10.1186/1475-2840-10-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037308/
https://www.ncbi.nlm.nih.gov/pubmed/21251281
http://dx.doi.org/10.1186/1475-2840-10-7

Ejemplares similares